secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122771
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron posts Q3 RYTELO revenue of $28.2M; secures up to $375M in financing
-------------------------------------------------------------------------

- Net product revenue of $28.2M from RYTELO in first full quarter of U.S. launch.
- Net loss of $26.4M ($0.04 per share) vs. $44.8M loss in Q3 2023.
- Total operating expenses guidance for FY2024 set at $260M–$270M.
- Received $250M gross proceeds: $125M from Royalty Pharma, $125M from Pharmakon loan.
- Additional $125M debt available; $86.5M Hercules loan repaid and terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/0000950170-24-122771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017024122771/gern-20241101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer